Message from the editors to our reviewers

Robert A. Gross; David S. Knopman; Gregory D. Cascino; John R. Corboy; Mitchell S.V. Elkind; Andrew G. Engel; Jonathan W. Mink; Richard M. Ransohoff; Ryan J. Uitti; Bradford B. Worrall

doi:10.1212/WNL.0b013e3182619224

Message from the editors to our reviewers

Robert A. Gross, David S. Knopman, Gregory D. Cascino, John R. Corboy, Mitchell S.V. Elkind, Andrew G. Engel, Jonathan W. Mink, Richard M. Ransohoff, Ryan J. Uitti, Bradford B. Worrall

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	5-12
Number of pages	8
Journal	Neurology
Volume	79
Issue number	1
DOIs	https://doi.org/10.1212/WNL.0b013e3182619224
State	Published - Jul 3 2012

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e3182619224

Cite this

@article{9e02ff2535094f5db98400e05ab5448c,

title = "Message from the editors to our reviewers",

author = "Gross, {Robert A.} and Knopman, {David S.} and Cascino, {Gregory D.} and Corboy, {John R.} and Elkind, {Mitchell S.V.} and Engel, {Andrew G.} and Mink, {Jonathan W.} and Ransohoff, {Richard M.} and Uitti, {Ryan J.} and Worrall, {Bradford B.}",

note = "Funding Information: Dr. Engel receives research funding from the NIH and from the Muscular Dystrophy Association. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Dr. Knopman serves on a Data Safety Monitoring Board for Lilly, and is an investigator for clinical trials sponsored by Baxter Pharmaceuticals, Elan Pharmaceuticals, and Forest Pharmaceuticals. He participated in two single session consultancies, one with Janssen and another with Merck, in which the honoraria were turned over to his institution. Dr. Knopman is supported by grants U01 AG 06786 (Mayo Alzheimer's Disease Patient Registry, R.C. Petersen PI) , P50 AG 16574 (Mayo Alzheimer's Disease Research Center, R.C. Petersen PI) , U01 AG 10483-7 (Alzheimer's Disease Cooperative Study, P. Aisen PI) , R01 AG11378-16 (Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging, C. Jack PI) , R01 HL96917 (The ARIC Neurocognitive Study, Thomas Mosley PI) , R01 AG032306 (Frontotemporal Lobar Degeneration Neuroimaging Initiative, H. Rosen PI) , R01 AG037551 (Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Anne Murray PI) . He is Deputy Editor of Neurology for which he receives compensation from the AAN. Funding Information: Dr. Mink has received research support from NIH/NINDS and the CDC. Dr. Mink serves on the Board of Scientific Counselors, NINDS. Dr. Mink has received travel funding from the Tourette Syndrome Association. He is an Editorial Board Member of Continuum, Pediatric Neurology, and the Journal of Child Neurology. Dr. Mink has received honoraria from the Tourette Syndrome Association, and receives an honorarium as Associate Editor of Neurology. Funding Information: Dr. Gross has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers' bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers' bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology. Funding Information: Dr. Ransohoff conducts research supported by the NIH, the National MS Society, Williams Family Foundation for MS Research, Chemocentryx, and Biogen-Idec. Dr. Ransohoff has received fees for preclinical consulting or honoraria for academic presentations from Novartis, Biogen-Idec, and Pfizer. He serves on Scientific Advisory, Medical Advisory, or Safety Monitoring Boards for Chemocentryx, Vertex, Merck, Glaxo Smith Kline, and Johnson & Johnson. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Dr. Cascino is coinvestigator of a study sponsored by NeuroPace , Inc, Sunnyvale, CA (RNS in Partial Epilepsy) and is supported by grant NS53998-03 (The Epilepsy Phenome/Genome Project). He receives an honorarium from the AAN as Associate Editor of Neurology. ",

year = "2012",

month = jul,

day = "3",

doi = "10.1212/WNL.0b013e3182619224",

language = "English (US)",

volume = "79",

pages = "5--12",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Message from the editors to our reviewers

AU - Gross, Robert A.

AU - Knopman, David S.

AU - Cascino, Gregory D.

AU - Corboy, John R.

AU - Elkind, Mitchell S.V.

AU - Engel, Andrew G.

AU - Mink, Jonathan W.

AU - Ransohoff, Richard M.

AU - Uitti, Ryan J.

AU - Worrall, Bradford B.

N1 - Funding Information: Dr. Engel receives research funding from the NIH and from the Muscular Dystrophy Association. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Dr. Knopman serves on a Data Safety Monitoring Board for Lilly, and is an investigator for clinical trials sponsored by Baxter Pharmaceuticals, Elan Pharmaceuticals, and Forest Pharmaceuticals. He participated in two single session consultancies, one with Janssen and another with Merck, in which the honoraria were turned over to his institution. Dr. Knopman is supported by grants U01 AG 06786 (Mayo Alzheimer's Disease Patient Registry, R.C. Petersen PI) , P50 AG 16574 (Mayo Alzheimer's Disease Research Center, R.C. Petersen PI) , U01 AG 10483-7 (Alzheimer's Disease Cooperative Study, P. Aisen PI) , R01 AG11378-16 (Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging, C. Jack PI) , R01 HL96917 (The ARIC Neurocognitive Study, Thomas Mosley PI) , R01 AG032306 (Frontotemporal Lobar Degeneration Neuroimaging Initiative, H. Rosen PI) , R01 AG037551 (Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Anne Murray PI) . He is Deputy Editor of Neurology for which he receives compensation from the AAN. Funding Information: Dr. Mink has received research support from NIH/NINDS and the CDC. Dr. Mink serves on the Board of Scientific Counselors, NINDS. Dr. Mink has received travel funding from the Tourette Syndrome Association. He is an Editorial Board Member of Continuum, Pediatric Neurology, and the Journal of Child Neurology. Dr. Mink has received honoraria from the Tourette Syndrome Association, and receives an honorarium as Associate Editor of Neurology. Funding Information: Dr. Gross has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers' bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers' bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology. Funding Information: Dr. Ransohoff conducts research supported by the NIH, the National MS Society, Williams Family Foundation for MS Research, Chemocentryx, and Biogen-Idec. Dr. Ransohoff has received fees for preclinical consulting or honoraria for academic presentations from Novartis, Biogen-Idec, and Pfizer. He serves on Scientific Advisory, Medical Advisory, or Safety Monitoring Boards for Chemocentryx, Vertex, Merck, Glaxo Smith Kline, and Johnson & Johnson. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Dr. Cascino is coinvestigator of a study sponsored by NeuroPace , Inc, Sunnyvale, CA (RNS in Partial Epilepsy) and is supported by grant NS53998-03 (The Epilepsy Phenome/Genome Project). He receives an honorarium from the AAN as Associate Editor of Neurology.

PY - 2012/7/3

Y1 - 2012/7/3

UR - http://www.scopus.com/inward/record.url?scp=84863562293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863562293&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3182619224

DO - 10.1212/WNL.0b013e3182619224

M3 - Editorial

AN - SCOPUS:84863562293

SN - 0028-3878

VL - 79

SP - 5

EP - 12

JO - Neurology

JF - Neurology

IS - 1

ER -

Message from the editors to our reviewers

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this